Unicycive Therapeutics Statistics
Total Valuation
UNCY has a market cap or net worth of $52.15 million. The enterprise value is $21.33 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, before market open.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
UNCY has 103.80 million shares outstanding. The number of shares has increased by 151.45% in one year.
| Current Share Class | 103.80M |
| Shares Outstanding | 103.80M |
| Shares Change (YoY) | +151.45% |
| Shares Change (QoQ) | -5.43% |
| Owned by Insiders (%) | 6.16% |
| Owned by Institutions (%) | 26.35% |
| Float | 70.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.79 |
| P/TBV Ratio | 1.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.61, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.61 |
| Quick Ratio | 3.09 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -416.70 |
Financial Efficiency
Return on equity (ROE) is -147.05% and return on invested capital (ROIC) is -110.63%.
| Return on Equity (ROE) | -147.05% |
| Return on Assets (ROA) | -62.85% |
| Return on Capital (ROIC) | -110.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.72M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.33% in the last 52 weeks. The beta is 2.28, so UNCY's price volatility has been higher than the market average.
| Beta (5Y) | 2.28 |
| 52-Week Price Change | +1.33% |
| 50-Day Moving Average | 0.44 |
| 200-Day Moving Average | 0.78 |
| Relative Strength Index (RSI) | 56.05 |
| Average Volume (20 Days) | 1,946,658 |
Short Selling Information
The latest short interest is 1.05 million, so 1.02% of the outstanding shares have been sold short.
| Short Interest | 1.05M |
| Short Previous Month | 1.05M |
| Short % of Shares Out | 1.02% |
| Short % of Float | 1.50% |
| Short Ratio (days to cover) | 0.74 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -29.17M |
| Pretax Income | -36.93M |
| Net Income | -24.10M |
| EBITDA | -29.15M |
| EBIT | -29.17M |
| Earnings Per Share (EPS) | -$0.49 |
Full Income StatementBalance Sheet
The company has $32.35 million in cash and $807,000 in debt, giving a net cash position of $31.54 million or $0.30 per share.
| Cash & Cash Equivalents | 32.35M |
| Total Debt | 807,000 |
| Net Cash | 31.54M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | 27.85M |
| Book Value Per Share | 0.28 |
| Working Capital | 27.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$26.47 million and capital expenditures -$50,000, giving a free cash flow of -$26.52 million.
| Operating Cash Flow | -26.47M |
| Capital Expenditures | -50,000 |
| Free Cash Flow | -26.52M |
| FCF Per Share | -$0.26 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |